Ind-Swift Ltd - IND-SWIFT Share Price

Sector: Pharmaceuticals | ISIN: INE788B01028
₹ 9.20 (0.00%) icon9 Jun, 2023, 12:26:00 PM
Open
₹ 9.20
Prev. Close
₹ 9.20
Turnover(lac)
₹ 0.67
Day's High
₹ 9.35
Day's Low
₹ 9.05
52 Wk High
₹ 14.50
52 Wk Low
₹ 6.60
Book Value
₹ -128.18
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 49.83
P/E
0.00
EPS
0.00
Div. Yield
0.00

Ind-Swift Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 6/9/2023 12:26:00 PM

    ₹ 9.2 0.00 0.00
  • Open
  • ₹ 9.2
  • Prev. Close
  • ₹ 9.2
  • Turnover(Lac.)
  • ₹ 1
  • Day's High
  • ₹ 9.35
  • Day's Low
  • ₹ 9.05
  • 52 Week's High
  • ₹ 14.5
  • 52 Week's Low
  • ₹ 6.6
  • Book Value
  • ₹ -128.18
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 49.83
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Ind-Swift Ltd Corporate Actions

16 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

28 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

28 Jan , 2023

12:00 AM

03 Nov , 2022

12:00 AM

03 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 Aug , 2022

12:00 AM

AGM

Announcement date: 18 Aug , 2022

View Details

29 Jul , 2022

12:00 AM

29 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Aug , 2022

12:00 AM

BookCloser

View Details

Ind-Swift Ltd SHAREHOLDING SNAPSHOT
09 June , 2023 | 12:26 PM

PROMOTER - TOTAL55.58%

Indian: 55.58%

Foreign: 0%

NON-PROMOTER - TOTAL 44.42%

Institutions: 0.00%

Non-Institutions: 44.42%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Ind-Swift Ltd News and Update

Article Image
  • 2 hours ago |
  • 5:54 PM

The company will use proceeds from the fresh issue towards working capital requirements and general corporate purposes.

Image not found
Article Image
ad IconAd Image

Ind-Swift Ltd FINANCIALS

Ind-Swift Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Ind-Swift Ltd

  • G Munjal
  • Managing Director & CEO
  • S R Mehta
  • Chairman & Exec. Director
  • V R Mehta
  • Joint Managing Director
  • Himanshu Jain
  • Non-Exec & Non-Independent Dir
  • N R Munjal
  • Non-Exec & Non-Independent Dir
  • Rishav Mehta
  • Non-Exec & Non-Independent Dir
  • S P Sharma
  • Non-Exec. & Independent Dir.
  • V K Arora
  • Non-Exec. & Independent Dir.
  • Subhash Chander Galhotra
  • Non-Exec. & Independent Dir.
  • Anoop Michra
  • Non-Exec. & Independent Dir.
  • Jagvir Singh Ahluwalia
  • Non-Exec. & Independent Dir.
  • Ginny Uppal
  • Company Sec. & Compli. Officer
  • Bhupinder Singh
  • Independent Director

Summary

Ind-Swift Ltd (ISL) is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.Ind-Swift Ltd was incorporated in the year 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care.In the year 2000, the company launched Super... Read More


Reports by Ind-Swift Ltd


Reports by Ind-Swift Ltd